Literature DB >> 25903015

Non-16/18 high-risk HPV infection predicts disease persistence and progression in women with an initial interpretation of LSIL.

Yasmin A Lyons1, Aparna A Kamat1, Haijun Zhou2, Dina R Mody2, Mary R Schwartz2, Christopher Hobday1, Yimin Ge2.   

Abstract

BACKGROUND: The current management strategy for women with low-grade squamous intraepithelial lesions (LSILs) is inefficient and expensive because of the inability to identify patients at high risk for disease progression. The current study was designed to determine the genotypic patterns of human papillomavirus (HPV) associated with the persistence and progression of cervical lesions in women with an initial interpretation of LSIL.
METHODS: One hundred sixty-seven women with LSIL on Papanicolaou tests collected between December 1, 2009 and March 30, 2011 were studied. HPV DNA was extracted from residual SurePath specimens, genotypes were determined with a DNA microarray containing 40 HPV genotype probes, and microarray data were confirmed by sequencing. Follow-up Papanicolaou tests and/or biopsies were performed within a 20- to 46-month period after the initial diagnosis.
RESULTS: Ninety-seven of the 167 cases with follow-up results were included in the study. Compared with the women with a regressed cervical lesion, those with a persistent cervical lesion (PCL) were significantly more commonly infected with high-risk human papillomavirus (HR-HPV) genotypes (P < .01) and particularly with non-16/18 HR-HPV genotypes (P < .05). The PCL group also had a significantly higher average number of HR-HPV genotypes and non-16/18 HPV genotypes per specimen (P < .01). Infection with HPV-16/18 genotypes was not significantly associated with the persistence or progression of cervical lesions.
CONCLUSIONS: Infection with non-16/18 HR-HPV genotypes but not with HPV-16/18 genotypes was a strong predictor of the persistence and progression of cervical disease upon follow-up. Genotyping solely for HPV-16/18 would miss the majority of patients with LSIL who progress to high-grade squamous intraepithelial lesions. Pooled HR-HPV tests provide a better predictive value than HPV-16/18 genotyping alone in guiding the clinical management of patients with LSIL.
© 2015 American Cancer Society.

Entities:  

Keywords:  human papillomavirus (HPV); human papillomavirus genotyping; low-grade squamous intraepithelial lesion; non-16/18 high-risk human papillomavirus genotypes; persistent cervical dysplasia; progression of cervical disease

Mesh:

Substances:

Year:  2015        PMID: 25903015     DOI: 10.1002/cncy.21549

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  5 in total

Review 1.  cfDNA detection for HPV+ squamous cell carcinomas.

Authors:  Kate Chatfield-Reed; Veronique P Roche; Quintin Pan
Journal:  Oral Oncol       Date:  2021-02-11       Impact factor: 5.337

2.  HPV-based screening for cervical cancer among women 55-59 years of age.

Authors:  Lovisa Bergengren; Gabriella Lillsunde-Larsson; Gisela Helenius; Mats G Karlsson
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

3.  High-risk human papillomavirus detection in self-collected vaginal samples compared with healthcare worker collected cervical samples among women attending gynecology clinics at a tertiary hospital in Pretoria, South Africa.

Authors:  Teboho Amelia Tiiti; Tebogo Loraine Mashishi; Varsetile Varster Nkwinika; Ina Benoy; Selokela Gloria Selabe; Johannes Bogers; Ramokone Lisbeth Lebelo
Journal:  Virol J       Date:  2021-09-23       Impact factor: 4.099

4.  Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China.

Authors:  Huihui Xu; Aifen Lin; Xiujuan Shao; Weiwu Shi; Yang Zhang; Weihua Yan
Journal:  Oncotarget       Date:  2016-12-13

5.  Mixed and nonvaccine high risk HPV types are associated with higher mortality in Black women with cervical cancer.

Authors:  Rachelle P Mendoza; Tahmineh Haidary; Elmer Gabutan; Ying Yin Zhou; Zaheer Bukhari; Courtney Connelly; Wen-Ching Lee; Yi-Chun Lee; Raj Wadgaonkar; Raag Agrawal; M A Haseeb; Raavi Gupta
Journal:  Sci Rep       Date:  2021-07-07       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.